HomeCompareDVAX vs MAIN

DVAX vs MAIN: Dividend Comparison 2026

DVAX yields 12.90% · MAIN yields 7.09%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MAIN wins by $47.90M in total portfolio value
10 years
DVAX
DVAX
● Live price
12.90%
Share price
$15.50
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$46.8K
Annual income
$2,879.44
Full DVAX calculator →
MAIN
Main Street Capital Corporation
● Live price
7.09%
Share price
$51.65
Annual div
$3.66
5Y div CAGR
72.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.95M
Annual income
$40,208,699.11
Full MAIN calculator →

Portfolio growth — DVAX vs MAIN

📍 MAIN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodDVAXMAIN
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, DVAX + MAIN cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
DVAX pays
MAIN pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DVAX
Annual income on $10K today (after 15% tax)
$1,096.77/yr
After 10yr DRIP, annual income (after tax)
$2,447.52/yr
MAIN
Annual income on $10K today (after 15% tax)
$602.32/yr
After 10yr DRIP, annual income (after tax)
$34,177,394.24/yr
At 15% tax rate, MAIN beats the other by $34,174,946.72/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DVAX + MAIN for your $10,000?

DVAX: 50%MAIN: 50%
100% MAIN50/50100% DVAX
Portfolio after 10yr
$24.00M
Annual income
$20,105,789.28/yr
Blended yield
83.78%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on DVAX right now

DVAX
Analyst Ratings
9
Buy
1
Hold
1
Sell
Consensus: Buy
Price Target
$27.00
+74.2% upside vs current
Range: $20.00 — $32.00
Altman Z
2.4
Piotroski
6/9
MAIN
Analyst Ratings
2
Buy
11
Hold
Consensus: Hold
Price Target
$65.25
+26.3% upside vs current
Range: $60.00 — $70.00
Altman Z
1.7
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DVAX buys
0
MAIN buys
0
No recent congressional trades found for DVAX or MAIN in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricDVAXMAIN
Forward yield12.90%7.09%
Annual dividend / share$2.00$3.66
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%72.7%
Portfolio after 10y$46.8K$47.95M
Annual income after 10y$2,879.44$40,208,699.11
Total dividends collected$20.6K$46.82M
Payment frequencyquarterlymonthly
SectorStockBDC
Analyst consensusBuyHold
Analyst price target$27.00$65.25

Year-by-year: DVAX vs MAIN ($10,000, DRIP)

YearDVAX PortfolioDVAX Income/yrMAIN PortfolioMAIN Income/yrGap
1← crossover$11,990$1,290.32$12,464$1,223.78$474.00MAIN
2$14,276$1,445.92$16,353$2,343.58$2.1KMAIN
3$16,884$1,608.88$23,105$4,724.42$6.2KMAIN
4$19,844$1,778.34$36,226$10,256.23$16.4KMAIN
5$23,186$1,953.40$65,426$24,707.64$42.2KMAIN
6$26,943$2,133.11$142,101$68,562.02$115.2KMAIN
7$31,145$2,316.51$388,521$228,799.95$357.4KMAIN
8$35,828$2,502.66$1,397,868$961,169.80$1.36MMAIN
9$41,026$2,690.60$6,884,663$5,313,459.69$6.84MMAIN
10$46,778$2,879.44$47,947,060$40,208,699.11$47.90MMAIN

DVAX vs MAIN: Complete Analysis 2026

DVAXStock

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.

Full DVAX Calculator →

MAINBDC

Main Street Capital Corporation is a business development company specializes in equity capital to lower middle market companies. The firm specializing in recapitalizations, management buyouts, refinancing, family estate planning, management buyouts, refinancing, industry consolidation, mature, later stage emerging growth. The firm also provides debt capital to middle market companies for acquisitions, management buyouts, growth financings, recapitalizations and refinancing. The firm seeks to partner with entrepreneurs, business owners and management teams and generally provides one stop financing alternatives within its lower middle market portfolio. It prefers to invest in air freight and logistics, auto components, building products, chemicals, commercial services, computers, construction and engineering, consumer finance, consumer services, electronic equipment, energy equipment and services, financial services, health care equipment, health care providers, hotels, restaurants, and leisure, internet software and services, IT Services, machinery, oil, gas and consumable fuels, paper and forest products, professional and industrial services, road and rail, software, specialty retail, telecommunication, consumer discretionary, energy, materials, technology, and transportation. The firm typically invests in lower middle market companies generally with annual revenues between $5 million and $300 million. It prefers to invest in ranging between $2 million and $75 million in equity investment and enterprise value in ranging between $3 million and $20 million. The firm typically prefers to invest in the range of $5 million and $50 million per transaction in debt investment value and in the range of $1 million and $20 million in annual EBITDA. The firm's middle market debt investments are made in businesses that are generally larger in size than its lower middle market portfolio companies. It takes 5 percent minority and up to 50 percent majority equity investments. Main Street Capital Corporation was founded in 2007 and is based in Houston, Texas with an additional office in Chojnów, Poland.

Full MAIN Calculator →
📬

Get this DVAX vs MAIN comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DVAX vs SCHDDVAX vs JEPIDVAX vs ODVAX vs KODVAX vs ARCCDVAX vs HTGCDVAX vs GBDCDVAX vs ORCC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.